Replies to post #213692 on Biotech Values

[swampboots]

Bone marrow transplantation had a rough 30 years and could have been dismissed but constantly tweaked with new approaches to improve this highly toxic strategy.

:
http://www.nature.com/bmt/journal/v52/n2/full/bmt2016258a.html?foxtrotcallback=true

[DewDiligence]

LLY,CureVac (private) ink deal for five cancer vaccines:

https://finance.yahoo.com/news/lilly-curevac-announce-global-collaboration-104500058.html

Under the terms of the agreement, CureVac will receive an upfront payment of $50 million and an equity investment of €45 million. CureVac is also eligible to receive more than $1.7 billion in development and commercialization milestones if all five vaccines are successfully developed, plus tiered royalties on product sales.

Lilly is responsible for target identification, clinical development and commercialization. CureVac will be responsible for mRNA design, formulation and manufacturing of clinical supply and retains the option to co-promote the vaccine products in Germany.

CureVac's proprietary RNActive technology will be used to deliver mRNA that ultimately directs the human immune system to target the encoded neoantigens.